 |
|
Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer.
Hong Joon Shin, Tae Ok Kim, Hyun Wook Kang, Su Young Chi, Hee Jung Ban, Soo Ok Kim, Yong Soo Kwon, In Jae Oh, Kyu Sik Kim, Yu Il Kim, Sung Chul Lim, Young Chul Kim
Tuberc Respir Dis. 2011;71(1):15-23. Published online 2011 Jul 1 DOI: https://doi.org/10.4046/trd.2011.71.1.15
|
|
Citations to this article as recorded by
 Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
Wenxiong Zhang, Yiping Wei, Dongliang Yu, Jianjun Xu, Jinhua Peng
BMC Cancer.2018;[Epub] CrossRef Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer
Wenxiong Zhang, Yiping Wei, Dongliang Yu, Jianjun Xu, Jinhua Peng
Medicine.2018; 97(16): e0460. CrossRef Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis
Zuyao Yang, Allan Hackshaw, Qi Feng, Xiaohong Fu, Yuelun Zhang, Chen Mao, Jinling Tang
International Journal of Cancer.2017; 140(12): 2805. CrossRef Quantitative and qualitative assessment of real world data comparative effectiveness research of systemic therapies in lung oncology: A systematic review
Bas J.M. Peters, Vivi E.M.T. Janssen, Franz M. Schramel, Ewoudt M.W. van de Garde
Cancer Epidemiology.2016; 44: 5. CrossRef
|